FDA D.I.S.C.O.: Burst Edition: FDA approvals of Opdualag (nivolumab and relatlimab-rmbw) for unre...
FDA D.I.S.C.O. Burst Edition: FDA approval Yescarta (axicabtagene ciloleucel) for adult patients ...Подробнее
FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanomaПодробнее
FDA Approves Frontline Nivolumab for Advanced MelanomaПодробнее
Dr. Eng on the FDA Approval of Nivolumab Plus Ipilimumab in CRCПодробнее
Should you treat melanoma with nivolumab and relatlimab (Opdualag)?Подробнее
Dr. Weber on the FDA Approval for Fixed-Dose of NivolumabПодробнее
FDA D.I.S.C.O. Burst Edition: FDA approvals of Jemperli (dostarlimab-gxly) for patients with mism...Подробнее
FDA D.I.S.C.O. Burst Edition: FDA approvals of Opdivo in combination with chemotherapy and Opdivo...Подробнее
FDA D.I.S.C.O. Burst Edition: FDA approvals of Imbruvica (ibrutinib) for pediatric patients with ...Подробнее
Dr. Luke on the FDA Approval of Adjuvant Nivolumab in MelanomaПодробнее
FDA Approval of Frontline Nivolumab/Ipilimumab Combo in RCCПодробнее
FDA considerations for approval of therapies in GI cancersПодробнее
Dr. Farago on the FDA Approval of Pembrolizumab for Lower PD-1 Cutoff NSCLCПодробнее
FDA Approvals in CINV and HER2+ Breast Cancer, Priority Review in Myelofibrosis, and MoreПодробнее
Dr. McDermott on Nivolumab Plus Ipilimumab in RCCПодробнее
FDA aproves OpdivoПодробнее
FDA Approval of Second-Dosing Schedule of NivolumabПодробнее
FDA approves OPDIVO® (nivolumab) in the United StatesПодробнее
